Emerging role of the peroxisome proliferator-activated receptor-gamma in hepatocellular carcinoma.

摘要: Hepatocellular carcinoma (HCC) is the major leading cause of cancer death worldwide. Hepatitis B virus, hepatitis C alcohol consumption, non-alcoholic fatty liver disease, and diabetes are risks for developing HCC. Until now, recurrence metastasis in HCC patients. Therefore, identification new effective molecular targets an urgent need treatment Peroxisome proliferator-activated receptor γ (PPARγ) a ligand-activated nuclear which could be activated by PPARγ agonists such as thiazolidinediones, natural ligand (such 15-deoxy-Δ12,14-prostaglandin J2, 15d-PGJ2). Increasing vitro vivo evidence has demonstrated that exhibit inhibitory role on tumor cell growth, migration, invasion, suggesting activation may play important regulation growth It been reported thiazolidinediones or overexpression virus-mediated gene transfer shown effects hepatoma cells, but expression level tissues still remains conflicting. Notably, novel agonist, honokiol, recently found to activate PPARγ/RXR heterodimer, also exhibited significant anti-cancer cells. In present review, we summarized studies development vivo. potential therapeutic target future